The Ingenia Communities Ltd (ASX: INA) share price is in focus after the company rejected a revised takeover proposal, stating it undervalues the business. Warburg Pincus increased its non-binding indicative offer to $5.05 cash per stapled security, up from $4.75, but Ingenia’s board concluded the proposal is not in the best interests of its securityholders.

What did Ingenia Communities report?

• Received a revised, non-binding indicative takeover offer at $5.05 per stapled security
• Offer followed a prior bid at $4.75 per security
• Ingenia Board, supported by independent financial and legal advice, rejected the new proposal
• The proposal was conditional on due diligence and regulatory approvals
• Ingenia’s market capitalisation stands at approximately $1.7 billion

What else do investors need to know?

Ingenia’s board engaged financial adviser Greenhill, a Mizuho affiliate, and external legal counsel, showing its commitment to a careful and thorough assessment of offers. The board remains open to alternative proposals that offer compelling value and serve the best interests of securityholders.

The company continues to focus on delivering its strategic plan. Securityholders are advised that no action is required regarding the revised offer and Ingenia remains committed to growth through acquisition and development.

What’s next for Ingenia Communities?

Ingenia will keep executing its current strategy, which aims to deliver long-term value for securityholders. The board indicated confidence in the company’s direction and growth path, and will continue to consider any future proposals that adequately reflect Ingenia’s value.

The company operates 96 communities and has a strong platform for ongoing expansion, focused on Australia’s growing seniors’ market.

Ingenia Communities share price snapshot

Over the past 12 months, Ingenia shares have declined 22%, trailing the S&P/ASX 200 Index (ASX: XJO), which has declined 1% over the same period.

View Original Announcement

The post Ingenia Communities rejects revised $5.05 takeover offer appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• Here are the top 10 ASX 200 shares today
• Why are Ingenia shares soaring today?
• Ingenia Communities Group rejects takeover offer, backs growth strategy
• Ingenia Communities proposes to acquire Peet, boosting growth

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

CSL Ltd (ASX: CSL) shares have clawed back serious ground in recent months, climbing 10% over the past month and 29% over the past six months. Even so, the ASX biotech stock remains 12% below where it stood a year ago.

The next test looms larger, though: the psychological $200 barrier. Clearing it won’t be a gimme. The $85 billion healthcare giant still has to prove it can deliver on several fronts before that milestone becomes more than just a broker’s spreadsheet fantasy.

The good news? CSL has actually laid out the roadmap. Now it just has to walk it.

The Behring problem, and the Behring fix

Everything starts with CSL Behring, by far the group’s biggest business and the one that’s caused the most headaches. After a rough patch, management is now promising a return to mid-single-digit revenue growth in FY27, with immunoglobulin sales expected to climb at a mid-to-high single-digit clip.

That’s not just corporate optimism. Demand for immunoglobulin remains genuinely strong, and CSL is squeezing more out of its plasma collection and manufacturing process at the same time. If Behring turns the corner, it drags the whole group with it.

New kids on the block

CSL isn’t relying on Behring alone. ANDEMBRY and HEMGENIX both posted strong uptake in FY26, and management expects that momentum to keep building.

If these newer therapies can scale into genuine earnings contributors, they give CSL something it’s lacked for a while: a growth story that doesn’t depend entirely on plasma.

Cost-cutting isn’t just noise

CSL’s transformation program has actual receipts. The company banked around US$176 million in cost savings during FY26 – ahead of schedule – with more coming in FY27. Roughly half of those incremental savings are being ploughed straight back into growth initiatives.

If revenue growth and cost discipline both fire at once, that’s a genuine earnings tailwind, not just a management slide deck promise.

The part nobody wants to talk about

Here’s the catch. CSL expects Vifor revenue to fall roughly 25% in FY27, hammered by generic competition in iron products. Seqirus, meanwhile, is only expected to scrape out low-single-digit growth.

Translation: Behring and the new therapies need to do the heavy lifting almost entirely on their own, while the rest of the portfolio does its best impression of dead weight.

Brokers are starting to bite

That improving – if uneven – outlook is enough to get some brokers genuinely excited. In September, RBC Capital Markets upgraded CSL to outperform and hiked its price target from $148 all the way to $213. That points to a 21% upside at the current share price level.

RBC’s bullish call rests on a simple bet: that Behring’s recovery can outrun the drag from Vifor and Seqirus, and earnings growth returns from here.

Barrenjoey followed with an upgrade to overweight and a $180 target.

Not everyone’s convinced. Citi is stuck at hold with a $160 target, while UBS sits at buy with $181.

Foolish takeaway

The path to $200 isn’t a straight line. It’s a bet that demand for immunoglobulins stays strong, new therapies scale quickly, cost savings keep flowing, and the weak links stop bleeding.

Leadership uncertainty adds another variable to the $200 case. In a notice of annual general meeting lodged with the ASX last week, CSL chair Brian McNamee said the search for a new Chief Executive Officer was well-advanced, though still ongoing.

Investors will want clarity on who’s steering the recovery before fully buying into it.

That’s a lot of boxes to tick. But if CSL ticks them, $200 starts looking like the obvious next stop.

The post Why brokers think CSL shares could be on track for $200 appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Coles, NAB, CSL shares
• ASX 200 healthcare shares lead a weaker market amid 82% chance of a rate hike
• How much passive income could I make by investing $500 a month in ASX shares?
• Are BHP, CBA, and CSL shares top buys?
• 6 ASX 200 shares boosted by brokers this week

Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Share prices of many ASX shares have fallen recently due to worries about bond yields, private credit uncertainties, AI, the Middle East, inflation and rising interest rates. There’s a lot to worry about for investors.

With all of the above in mind, it’s not surprising that some interest rate-sensitive ASX shares are down (close) to their 52-week lows.

Below are two of my favourites right now at a low point.

Centuria Industrial REIT (ASX: CIP)

Interest rates act like gravity on property prices – when rates go down, interest costs fall, and property values are likely to rise. The reverse is also true. With interest rates anticipated to rise this year, the market has pushed the Centuria Industrial REIT share price down 20% in the past year to a 52-week low.

This business owns a portfolio of industrial properties across Australia. I think it’s appealing to be able to buy a slice of so many properties in just a single transaction.

Property values do change over time, and it’s hard to know exactly what the ASX share’s property portfolio is worth without actually going to sell it, which the business isn’t going to do.

However, we can look at the REIT’s distribution as a way to see how attractive it is.

The business grew its annual distribution by 3% in FY26 and expects to grow its payout by another 3% to 17.3 cents per unit. That’s a forward distribution yield of 6.1%. To me, that’s an excellent yield from a business like this.

When rates do eventually come down, I think this valuation could make it seem like a cheap ASX share.

JB Hi-Fi Ltd (ASX: JBH)

JB Hi-Fi is another name that has seen a sell-off. The JB Hi-Fi share price has dropped 44% in the past year, and it’s now close to its 52-week low.

Inflation of living costs and higher interest rates are already causing headwinds, and investors are feeling negative. I think it’s been heavily oversold.

For July 2026 (the first month of FY27), the business provided a sales update showing total sales dropped 0.5% for JB Hi-Fi Australia and declined 1.7% for The Good Guys. Positively, JB Hi-Fi New Zealand’s sales growth was 20.9%.

At this stage, sales are only slightly down in Australia.

I believe JB Hi-Fi Australia is well-placed to serve customers with its scale benefits, very competitively priced products, a wide product range, a productive sales floor, and an expanding network of locations in Australia and New Zealand.  

Using the projection on CommSec, the JB Hi-Fi share price is valued at under 15 times FY27’s estimated earnings, with earnings growth projected in FY28 and FY29. That makes it look like a cheap ASX share to me.

The post 2 cheap ASX shares near 52-week lows I’d buy today appeared first on The Motley Fool Australia.

More reading

• ASX retail shares are down 13% in 2026. Here’s what Morgan Stanley is worried about
• 3 ASX dividend stocks to provide passive income through retirement 
• JB Hi-Fi vs Harvey Norman: Which dividend stock wins?
• Here are the top 10 ASX 200 shares today
• 2 ASX blue-chip shares offering big dividend yields

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.